Sinovac Biotech Ltd. (SVA) announces encouraging results from a preclinical animal study for its inactivated SARS-CoV-2 vaccine candidate.
The challenge study in mice, rats and rhesus
macaques showed that it was safe and provided complete protection
against SARS-CoV-2 strains (in the primates) according to Chairman
Weidong Yin.
A Phase 1 study in healthy human volunteers is underway.
Trading in the U.S. has been suspended since
February 22, 2019, pending the submission of additional information
requested by Nasdaq.
https://seekingalpha.com/news/3570106-sinovac-covidminus-19-vaccine-shows-positive-effect-in-preclinical-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.